Today: 19 April 2026
Subscribe
Browse Category

TSX:MXG 9 February 2026 - 11 February 2026

GE Vernova stock jumps 4% to $823 as a 2030 turbine-slot deal fuels the run

GE Vernova stock jumps 4% to $823 as a 2030 turbine-slot deal fuels the run

GE Vernova shares climbed 4.1% to $823.67 Wednesday after Maxim Power reserved a 7HA.02 gas turbine slot for 2030 delivery, requiring a deposit in 2026. The agreement covers Maxim’s 400-megawatt Prairie Lights project in Alberta. Trading volume reached 2.7 million shares. Investors now await GE Vernova’s April 22 earnings webcast for updates on orders and margins.
11 February 2026
···

Stock Market Today

  • ATI Share Price Surges 262% in One Year, But Valuation Flags Overvaluation
    April 18, 2026, 9:38 PM EDT. Shares of ATI have surged 261.9% over the past year to close at $164.66, fueled by interest in its Aerospace & Defense role. Despite strong gains, ATI scores 0 out of 6 on valuation checks. A Discounted Cash Flow (DCF) model estimates ATI's intrinsic value at approximately $142.92 per share, suggesting the stock is overvalued by 15.2%. The DCF uses projected free cash flows rising from $362.7 million to $1.19 billion by 2035. Investors are questioning whether current prices reflect fundamentals or if sentiment has outpaced growth prospects. Price-to-Earnings (P/E) ratios remain a quick gauge of value, linking share price to current earnings, but must account for growth and risk outlooks. ATI's elevated valuation hints at potential risks despite stellar price momentum.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop